

## Triumeq/Triumeq PD (abacavir/dolutegravir/lamivudine) – Expanded indication

- On June 15, 2023, the [FDA approved](#) ViiV Healthcare's [Triumeq and Triumeq PD \(abacavir/dolutegravir/lamivudine\)](#), for the treatment of HIV-1 infection in adults and in pediatric patients aged at least 3 months and weighing at least 6 kg.
  - Triumeq and Triumeq PD were previously approved for this indication in adults and in pediatric patients weighing at least 10 kg.
  - Triumeq and Triumeq PD alone are not recommended in patients with resistance-associated integrase substitutions or clinically suspected integrase strand transfer inhibitor resistance because the dose of dolutegravir in Triumeq and Triumeq PD is insufficient in these subpopulations.
- Triumeq and Triumeq PD carry a boxed warning for hypersensitive reactions and exacerbations of hepatitis B.
- The recommended dose of Triumeq PD for the treatment of HIV-1 infection in pediatric patients 6 kg to < 10 kg is 3 tablets once daily (180 mg abacavir, 15 mg dolutegravir, and 90 mg lamivudine once daily). Triumeq PD is administered as a tablet for oral suspension.
  - Triumeq tablets are not recommended for patients 6 kg to < 10 kg.
  - Refer to the Triumeq and Triumeq PD drug label for dosing for other age groups.